Azilsartan medoxomil + chlorthalidone versus olmesartan medoxomil + hydrochlorothiazide in hypertension with moderate renal impairment

Phase 3, randomised, open-label trial of azilsartan medoxomil, chlorthalidone, olmesartan and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoint: Percentage of subjects with at least 1 adverse event. Started Jan 2011; status: completed.